Palvella Therapeutics

Update in progress

PVLA (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on therapies for serious and rare genetic skin diseases. Its lead candidate, QTORIN rapamycin, is a 3.9% anhydrous topical gel in Phase 3 for microcystic lymphatic malformations and Phase 2 for cutaneous venous malformations. It also targets angiokeratomas and other mTOR-driven skin diseases, plus QTORIN pitavastatin for disseminated superficial actinic porokeratosis. Based in Wayne, Pennsylvania.

Company score

Sentiment: 0.43; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.33; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.27; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive